Itraconazole Viatris

Itraconazole, the active ingredient in Itraconazole Viatris, is a triazole antifungal presented as an oral formulation for oral use. It treats a range of systemic and superficial fungal infections, including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, aspergillosis and candidiasis, in patients for whom antifungal therapy is indicated.

GNH USA supplies Itraconazole Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to health‑care institutions across multiple regions.

Itraconazole is a triazole antifungal used to treat a variety of mycotic infections by inhibiting ergosterol synthesis. - Dermatophytosis: clears skin lesions by reducing fungal growth. - Onychomycosis: eradicates nail‑bed infection and promotes healthy nail regrowth. - Blastomycosis: eliminates systemic Blastomyces organisms and resolves pulmonary involvement. - Histoplasmosis: controls disseminated Histoplasma infection in affected organs. - Aspergillosis: suppresses invasive Aspergillus species in immunocompromised patients. - Candidiasis: treats mucosal and systemic Candida infections.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools, often self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function, especially in high‑risk patients. - Severe skin reactions: rash, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.

Itraconazole requires careful monitoring due to its pharmacologic profile. - Monitor liver function: baseline and periodic tests are recommended because of potential hepatotoxicity. - Assess cardiac status: avoid in patients with existing heart failure or significant ventricular dysfunction. - Review concomitant medications: many drugs affect or are affected by CYP3A4 metabolism. - Pregnancy and lactation: use only if the potential benefit outweighs the risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Itraconazole has a notable interaction profile that clinicians must consider. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce itraconazole exposure. - Certain antiarrhythmics (e.g., quinidine): can increase risk of cardiac toxicity. Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (e.g., simvastatin): may raise statin levels, increasing myopathy risk. - Proton pump inhibitors: may decrease itraconazole absorption; assess timing of administration. - Anticoagulants (e.g., warfarin): may require INR monitoring due to altered metabolism.